Tubulointerstitial injury

Tubulointerstitial injury (TII) is a pathological process characterized by damage to the renal tubules and the surrounding interstitial tissue, serving as a primary hallmark of both acute and chronic kidney diseases. It involves a complex sequence of events, including tubular epithelial cell injury, the recruitment of inflammatory cells, and the activation of myofibroblasts, which leads to the excessive deposition of extracellular matrix, or fibrosis (StatPearls, NBK542220; PubMed, 15596324). Unlike many glomerular diseases, the severity of tubulointerstitial injury is often the most reliable predictor of long-term renal functional decline and progression to end-stage renal disease (ESRD). While not a single molecular target, it is the focus of intense therapeutic research aimed at blocking pathways such as the renin-angiotensin-aldosterone system (RAAS), TGF-beta signaling, and oxidative stress to preserve kidney function. Current clinical interventions primarily utilize ACE inhibitors, ARBs, and SGLT2 inhibitors to mitigate the stressors that drive this injury and slow the transition from acute damage to permanent fibrosis (NIH/NIDDK; PubMed, 29033100).

Other names

Tubulointerstitial fibrosisRenal tubulointerstitial injuryTubulointerstitial nephritisTIITubulointerstitial disease

Reduction of tubulointerstitial damage through inhibition of the renin-angiotensin-aldosterone system (RAAS), modulation of mineralocorticoid receptors, or inhibition of pro-fibrotic and pro-inflammatory signaling cascades (e.g., TGF-beta, SGLT2 pathways).